Sarah Ferber

This inventor holds 7 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Tel Hashomer Medical Research Infrastructure and Services Ltd., Orgenesis Ltd.. Active years: 2016-2023.

USPTO Granted Patents = 7 (Patent Applications = 2)

% Patents Active = 42.9

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 1.0

ph-index = 2

Forward Citations = 7(Granted Patents)

Company Filing History:

7 out of 131

Tel Hashomer Medical Research Infrastructure and Services Ltd.

where one patent can have more than one assignee

Years Active: 2016-2023

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11617769 - Methods of transdifferentiation and methods of use thereof (2023-04-04),

2. 10975354 - Transdifferentiated cell populations and methods of use thereof (2021-04-13),

3. 10947509 - Cell populations, methods of transdifferentiation and methods of use thereof (2021-03-16),

4. 10668107 - Methods of transdifferentiation and methods of use thereof (2020-06-02),

5. 10179151 - Methods of transdifferentiation and methods of use thereof (2019-01-15),

6. 9982236 - Cell populations, methods of transdifferentiation and methods of use thereof (2018-05-29),

7. 9481894 - Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues (2016-11-01),

Title: The Innovative Journey of Inventor Sarah Ferber

Introduction: Sarah Ferber, an accomplished inventor based in Tel Aviv, Israel, has made remarkable contributions to the field of medical research and biotechnology. With a total of seven patents to her name, she is recognized for her innovative approaches to cell manufacturing and transdifferentiation.

Latest Patents: Among her latest patents, Sarah has developed groundbreaking methods for creating human insulin-producing cells from non-pancreatic β-cells. One of her notable inventions is a method that enhances insulin content and glucose-regulated secretion of insulin, making strides towards effective diabetes treatments. Furthermore, she has disclosed methods for producing transdifferentiated populations of human insulin-producing cells and enriching β-cells with a greater capacity for transcription factor-induced transdifferentiation into pancreatic β-cell phenotypes.

Career Highlights: Throughout her career, Sarah has worked with esteemed organizations that focus on advancing medical research. Her involvement with Tel Hashomer Medical Research Infrastructure and Services Ltd. and Orgenesis Ltd. has allowed her to collaborate with leading experts in the field, thus contributing significantly to her areas of expertise.

Collaborations: Sarah's work in transdifferentiation and cell manufacturing has garnered attention from various research institutions and companies. Her collaborative efforts with Tel Hashomer Medical Research Infrastructure and Services Ltd. and Orgenesis Ltd. have been instrumental in bringing her innovative ideas to life while paving the way for future advancements in biotechnology.

Conclusion: In summary, Sarah Ferber's inventive spirit and dedication to advancing medical research have made her a valuable figure in her field. With her seven patents showcasing innovative methods for cell production and transdifferentiation, she continues to lead the way in medical technology and inspires future inventors.